Ublituximab-Xiyl 150 mg/6 mL Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 150 mg/6 mL

Reference Brands: Briumvi (USA/EU)

Category: Neurology

ublituximab-xiyl is a CD20-directed monoclonal antibody that targets B-cells responsible for nerve damage in multiple sclerosis. It helps reduce relapses and slow disability progression in adults with relapsing forms of MS. Administered as an intravenous infusion, it offers a targeted approach with fewer infusion sessions compared to some other MS therapies.

Product Description:

Ublituximab is a chimeric anti-CD20 monoclonal antibody engineered for enhanced antibody-dependent cellular cytotoxicity. Its Fc region carries reduced fucose, which increases binding to the FcγRIIIa receptor on natural killer cells, so B cells are depleted efficiently at a lower dose than other anti-CD20 antibodies. It binds a different CD20 epitope from rituximab and ocrelizumab.

It is used for relapsing forms of multiple sclerosis in adults. The practical advantage is infusion time: after a 150 mg first infusion and a 450 mg dose two weeks later, maintenance doses are given every six months as a one-hour infusion, compared with several hours for ocrelizumab. In trials it reduced annualised relapse rate compared with teriflunomide. Infusion reactions are common, mostly with the first dose, and premedication is standard. Infection risk rises, hepatitis B is screened before starting, and immunoglobulin levels are monitored during long-term treatment.

Sourcing notes. Originator biologic, on patent, no biosimilar. Approved in the US and the EU, with registration elsewhere still developing. It competes directly with ocrelizumab and ofatumumab, and in some markets with off-label rituximab, which is much cheaper; that comparison often drives formulary decisions. Cold chain. Supply is through authorised distribution, and infusion-centre capacity shapes demand.